BRAF and melanoma: In 2011, the United States Food and Drug Association approved two new treatments for advanced, unresectable melanoma - the antagonist cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibody, ipilimumab, and the targeted BRAF inhibitor, vemurafenib.